Double Bond Pharmaceutical (DBP) Q3 2025 earnings summary

Executive summary

• Advanced due diligence discussions ongoing with several potential partners for lead product S1053 (Temodex), seen as a potential game changer in brain tumor treatment.

• Continued conceptual development of S1053 and progress in other pipeline products.

• Strong shareholder engagement noted during an intensive phase for the company.

Financial highlights

• Q3 2025 total revenue was 0.1 MSEK, down from 0.2 MSEK in Q3 2024.

• Operating result for Q3 2025 was -0.5 MSEK, improved from -1.7 MSEK in Q3 2024.

• Net result for Q3 2025 was -0.5 MSEK, compared to -0.9 MSEK in Q3 2024.

• For Jan–Sep 2025, total revenue was 0.1 MSEK (0.9 MSEK in 2024), operating result -1.2 MSEK (-5.8 MSEK), net result -2.0 MSEK (-8.3 MSEK).

• Earnings per share for Q3 and Jan–Sep 2025 were -0.01, unchanged from Q3 2024 and improved from -0.08 for Jan–Sep 2024.

Outlook and guidance

• Ongoing partner discussions and product development expected to enhance product value.

• Updates on other pipeline products to be communicated via press releases.